Efficacy and Safety of an Intravenous C1-Inhibitor Concentrate for Long-Term Prophylaxis in Hereditary angioedema | Zendy

Timothy Craig | Zendy; Ralph Shapiro | Zendy; Arthur B. Vegh | Zendy; James Baker | Zendy; Jonathan A. Bernstein | Zendy; Paula Busse | Zendy; Markus Magerl | Zendy; Inmaculada MartinezSaguer | Zendy; Marc A. Riedl | Zendy; William Lumry | Zendy; Debora WilliamsHerman | Zendy; Jonathan M. Edelman | Zendy; Henrike Feuersenger | Zendy; Thomas Machnig | Zendy; Mikhail Rojavin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy and Safety of an Intravenous C1-Inhibitor Concentrate for Long-Term Prophylaxis in Hereditary angioedema

Author(s) -

Timothy Craig,

Ralph Shapiro,

Arthur B. Vegh,

James Baker,

Jonathan A. Bernstein,

Paula Busse,

Markus Magerl,

Inmaculada MartinezSaguer,

Marc A. Riedl,

William Lumry,

Debora WilliamsHerman,

Jonathan M. Edelman,

Henrike Feuersenger,

Thomas Machnig,

Mikhail Rojavin

Publication year - 2017

Publication title -

allergy and rhinology

Language(s) - English

Resource type - Journals

eISSN - 2152-6575

pISSN - 2152-6567

DOI - 10.2500/ar.2017.8.0192

Subject(s) - hereditary angioedema , medicine , c1 inhibitor , angioedema , term (time) , anesthesia , dermatology , physics , quantum mechanics

The plasma-derived, pasteurized, nanofiltered C1-inhibitor concentrate (pnfC1-INH) is approved in the United States as an intravenous (IV) on-demand treatment for hereditary angioedema (HAE) attacks, and, in Europe, as on demand and short-term prophylaxis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research